Hirudin in haemodialysis

Area of Science:

• Biomedical Engineering
• Pharmacology
• Nephrology

Background:

• Hemodialysis requires effective anticoagulation to prevent circuit clotting.
• Traditional anticoagulants may pose risks or be less effective in certain patient populations.
• Recombinant hirudin offers a potential alternative anticoagulant for hemodialysis.

Purpose of the Study:

• To evaluate the efficacy of recombinant hirudin as an anticoagulant in hemodialysis.
• To assess recombinant hirudin's ability to prevent clotting and fibrin deposition during extracorporeal circulation.
• To investigate the pharmacokinetic properties and membrane compatibility of recombinant hirudin.

Main Methods:

• Nephrectomized dogs were used as an experimental model for hemodialysis.
• Recombinant hirudin's penetration through different dialyzer membranes was assessed.
• Pharmacokinetic behavior and anticoagulant activity of recombinant hirudin were analyzed during hemodialysis.

Main Results:

• Recombinant hirudin demonstrated efficient prevention of thrombus formation in experimental hemodialysis.
• The study confirmed the capability of recombinant hirudin to inhibit clotting system activation.
• Fibrin deposition during hemodialysis was effectively prevented by recombinant hirudin.

Conclusions:

• Recombinant hirudin is an efficient anticoagulant for preventing thrombus formation during hemodialysis.
• The findings support the suitability of recombinant hirudin for anticoagulation in extracorporeal circulation.
• Recombinant hirudin shows promise as a safe and effective anticoagulant agent in hemodialysis procedures.